Tamer I Khayal sold $394k of TMDX
Chief Commercial Officer at TransMedics Group, Inc.. 2,960 shares at an average of $133.10, traded Jun 3, 2024, filed Jun 5, 2024.
Score components
- +15RoleOfficer
- +16Trade size$394k at market
- +5Share of holdings soldSold 12% of holdings
- +15Cluster6 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +12.8%, 3m +11.8%, 6m -46.5%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-24-069423, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 3, 2024 | MOption exercise Common Stock10b5-1 | +1,459 | $38.46 | $56k | 22,302 | Jun 5, 2024 |
| Jun 3, 2024 | MOption exercise Common Stock10b5-1 | +417 | $66.10 | $28k | 22,719 | Jun 5, 2024 |
| Jun 3, 2024 | MOption exercise Common Stock10b5-1 | +1,084 | $13.28 | $14k | 23,803 | Jun 5, 2024 |
| Jun 3, 2024 | SOpen-market sale Common Stock10b5-1 | -105 | $129.92 | $14k | 23,698 | Jun 5, 2024 |
| Jun 3, 2024 | SOpen-market sale Common Stock10b5-1 | -219 | $130.79 | $29k | 23,479 | Jun 5, 2024 |
| Jun 3, 2024 | SOpen-market sale Common Stock10b5-1 | -539 | $131.87 | $71k | 22,940 | Jun 5, 2024 |
| Jun 3, 2024 | SOpen-market sale Common Stock10b5-1 | -921 | $132.71 | $122k | 22,019 | Jun 5, 2024 |
| Jun 3, 2024 | SOpen-market sale Common Stock10b5-1 | -567 | $133.67 | $76k | 21,452 | Jun 5, 2024 |
| Jun 3, 2024 | SOpen-market sale Common Stock10b5-1 | -152 | $134.66 | $20k | 21,300 | Jun 5, 2024 |
| Jun 3, 2024 | SOpen-market sale Common Stock10b5-1 | -457 | $135.97 | $62k | 20,843 | Jun 5, 2024 |
| Jun 3, 2024 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -1,459 | $0.00 | $0 | 13,125 | Jun 5, 2024 |
| Jun 3, 2024 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -417 | $0.00 | $0 | 13,766 | Jun 5, 2024 |
| Jun 3, 2024 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -1,084 | $0.00 | $0 | 22,750 | Jun 5, 2024 |
Related signals
Other insiders at TransMedics Group, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 36Weak | TMDXbuy TransMedics Group, Inc. | David Weill director | $109k 1,336 shares | +9% | |
| 31Weak | TMDXsell TransMedics Group, Inc. | Thomas James Gunderson director | $722k 9,624 shares | -37% | |
| 52Moderate | TransMedics Group, Inc. | Stephanie Lovell director | $178k 1,193 shares | -29% | |
| 38Weak | TransMedics Group, Inc. | David Weill director | $524k 3,571 shares | -23% | |
| 46Moderate | TransMedics Group, Inc. | Nicholas Corcoran See remarks | $413k 2,966 shares | -9% | |
| 67Notable | TransMedics Group, Inc. | Gerardo Hernandez Chief Financial Officer | $1.1M 7,611 shares | -51% | |
| 40Moderate | TransMedics Group, Inc. | Anil P. Ranganath See remarks | $120k 864 shares | -6% | |
| 48Moderate | TransMedics Group, Inc. | Gerardo Hernandez Chief Financial Officer | $128k 920 shares | -6% | |
| 46Moderate | TransMedics Group, Inc. | David Weill director | $693k 5,000 shares | -29% | |
| 37Weak | TransMedics Group, Inc. | Anil P. Ranganath See remarks | $436k 3,000 shares | -18% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.